Aktis Oncology Advances Actinium-Based Radiopharmaceutical Expansion with Additional Enrollment and In-House Supply

Recently, Aktis Oncology, an innovative company focused on developing targeted radiopharmaceuticals, officially disclosed the latest enrollment arrangements for two innovative targeted radiopharmaceutical studies based on Actinium-225. While continuing to advance dose-escalation trials, the company has substantially expanded supplemental patient enrollment for its two core pipeline candidates, AKY-1189 and AKY-2519, at selected dose levels, aiming to comprehensively observe and characterize their safety, tolerability, and preliminary antitumor activity, thereby accumulating detailed data support for subsequent pivotal clinical development.

Among them, AKY-1189, which targets Nectin-4, is currently undergoing scientific evaluation in the NECTINIUM-2 Phase Ⱬb clinical study, with indications covering locally advanced or metastatic urothelial carcinoma and other related solid tumors. The study has officially initiated supplemental enrollment at the 6 MBq dose level, with a planned maximum of 30 patients, to further clarify the clinical profile at this dose. Meanwhile, AKY-2519, which targets B7-H3, is being evaluated for efficacy in the BActinium-1 Phase Ⱬb study in metastatic castration-resistant prostate cancer (mCRPC). At the 9 MBq dose level, the trial is conducting supplemental enrollment separately for patient populations previously treated with and naive to PLUVICTO, with each cohort also planning to enroll up to 30 patients.

While its clinical development pipeline advances steadily, Aktis Oncology has also achieved a key breakthrough in supply chain infrastructure construction. The company's own Good Manufacturing Practice (GMP) production facility in Boston has now officially begun trial production of drug products, and the company plans to fully incorporate this in-house facility into the clinical supply manufacturing system for both drug candidates through a clinical trial application amendment. The company expects to officially supply clinical trial drugs from this facility in the first half of 2027, thereby effectively supplementing its existing external contract manufacturing and isotope supply network.

Industry analysis notes that as the clinical potential of targeted alpha therapy (TAT) in the treatment of refractory solid tumors continues to be validated, the stable supply of isotopes such as Actinium-225 and the construction of GMP-grade production capacity have become core factors constraining the commercialization of radiopharmaceutical companies. Through a dual-driven model of "continuous supplemental clinical enrollment + in-house GMP capacity construction," Aktis Oncology has not only accelerated the pace of its pipeline advancement but also explored a mature practical pathway for the autonomous and controllable supply chain of targeted radiopharmaceuticals globally.